Latest News and Press Releases

BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent...

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has...

Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today...

Recommends Against Electing WaterMill Nominee Jaime Vieser Ziopharm Continues to Recommend that Shareholders Support Company’s Strong Progress by Returning the GREEN Consent Revocation Card ...

Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates...

ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings Raise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm...

Continues to Execute on Strategy to Ensure Strong Long-Term Outlook Outlines Additions of Five Highly Qualified Industry Veterans to Board Over the Last 18 Months BOSTON, Nov. 20, 2020 (GLOBE...

– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM, and a Confirmed Partial Response – – Updated Interim Data...

– Pharmaceutical Executive with 20+ Years of Experience Across All Phases of Clinical Research Including IND Submissions, Trial Design and Regulatory Filings – – Former Chief Medical Officer for...

– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director – – Biotechnology Leader with 25+ Year Track Record of Creating...